{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T06:53:40Z","timestamp":1763621620465,"version":"3.45.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Systemic therapy is the standard treatment for patients with hepatitis B-related hepatocellular carcinoma (HCC) and portal vein invasion. Emerging evidence suggests that the combination of localized regional therapy, multikinase inhibitors (MKIs), and immune checkpoint inhibitors (ICIs) yields promising outcomes for advanced HCC. ICIs not only effectively control HCC progression but may also facilitate a HBsAg clearance for hepatitis B-associated HCC patients, characterized by sustained HBV DNA (Hepatitis B Virus Deoxyribonucleic Acid)and HBsAg clearance. This report details a case of hepatitis B cirrhosis with multifocal intrahepatic HCC and portal vein involvement, where the patient achieved complete response (CR) and HBsAg clearance following treatment with lenvatinib (an MKI), tislelizumab (a PD-1 inhibitor), and localized regional therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case summary<\/jats:title>\n                    <jats:p>A 61-year-old male with hepatitis B-related cirrhosis and advanced HCC with portal vein involvement underwent drug-loaded microsphere hepatic arterial chemoembolization (DEB-TACE) treatment. Additionally, the patient received a combination therapy of lenvatinib and tislelizumab. Following three DEB-TACE sessions, six months of lenvatinib, and seven cycles of tislelizumab, the patient attained CR and achieved HBsAg clearance of hepatitis B, as evidenced by the sustained absence of HBV DNA and HBsAg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The concurrent administration of DEB-TACE, lenvatinib, and tislelizumab demonstrated efficacy in achieving a HBsAg clearance for hepatitis B in a patient presenting with advanced HCC and portal vein tumor thrombosis. These findings suggest that a localized regimen incorporating MKIs and ICIs holds promise as a therapeutic approach for select cases of HBV-HCC, potentially leading to a HBsAg clearance of hepatitis B. Large-scale studies are warranted to validate these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1676514","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T06:15:28Z","timestamp":1763619328000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Complete response and HBsAg clearance of advanced hepatocellular carcinoma associated with hepatitis B by DEB\u2212TACE combined systematic therapy: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Baiguo","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufeng","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongsong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.molimm.2023.08.006","article-title":"Tumor-derived exosomes promote macrophages M2 polarization through miR-1-3p and regulate the progression of liver cancer","volume":"162","author":"Gu","year":"2023","journal-title":"Mol Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.05.044","article-title":"Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion","volume":"65","author":"Kokudo","year":"2016","journal-title":"J Hepatol"},{"key":"B3","article-title":"Factors influencing survival in hepatocellular carcinoma patients with macroscopic portal vein tumor thrombosis after surgery, with special reference to time dependency: a single-center experience of 381 cases","volume":"53","author":"Zhou","year":"2006","journal-title":"Hepatogastroenterology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1159\/000112805","article-title":"Hepatic arterial infusion chemotherapy with epirubicin in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis","volume":"72","author":"Ikeda","year":"2007","journal-title":"Oncology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v15.i3.447","article-title":"Transarterial chemoembolization plus stent placement for hepatocellular carcinoma with main portal vein tumor thrombosis: A meta-analysis","volume":"15","author":"Sui","year":"2024","journal-title":"World J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma [published correction appears in Hepatology. 2023 Dec 1;78(6):E105. doi: 10.1097\/HEP.0000000000000621","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiolchem.2025.108599","article-title":"Advancing explainable AI in healthcare: Necessity, progress, and future directions","volume":"119","author":"Mohapatra","year":"2025","journal-title":"Comput Biol Chem"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2020.00001","article-title":"Management and treatment of hepatocellular carcinoma with immunotherapy: a review of current and future options","volume":"8","author":"Ghavimi","year":"2020","journal-title":"J Clin Transl Hepatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.17998\/jlc.2021.09.24","article-title":"Advances in immune checkpoint inhibitors for hepatocellular carcinoma","volume":"21","author":"Han","year":"2021","journal-title":"J Liver Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e23775","DOI":"10.1002\/jcla.23775","article-title":"Serum potassium levels and prognosis in HBV-associated decompensated cirrhosis","volume":"35","author":"Huang","year":"2021","journal-title":"J Clin Lab Anal"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)30427-1","article-title":"Mortality, morbidity, and risk factors in China and its provinces, 1990\u20132017: a systematic analysis for the global burden of disease study 2017","volume":"394","author":"Zhou","year":"2017","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12818","article-title":"Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study","volume":"35","author":"Park","year":"2015","journal-title":"Liver Int"},{"key":"B15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2019.01.020","article-title":"Corrigendum to EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","author":"Raoul","year":"2018","journal-title":"J Hepatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-09-0280","article-title":"Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts","volume":"8","author":"Roland","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(02)08649-x","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2478\/raon-2023-0001","article-title":"Comparison of CalliSpheres(\u00ae) microspheres drug-eluting beads and conventional transarterial chemoembolization in hepatocellular carcinoma patients: a randomized controlled trial","volume":"57","author":"Shi","year":"2023","journal-title":"Radiol Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/hepr.12450","article-title":"Systematic review comparing the safety and efficacy of conventional and drug-eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma","volume":"45","author":"Xie","year":"2015","journal-title":"Hepatol Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12439","article-title":"Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma","volume":"29","author":"Huang","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn501113-20221224-00607","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (2022 version)","volume":"30","year":"2022","journal-title":"Chin J Hepatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e002305","DOI":"10.1136\/jitc-2020-002305","article-title":"Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma","volume":"9","author":"Deng","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S332420","article-title":"Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a multicenter retrospective study","volume":"8","author":"Wu","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1177\/10732748221111296","article-title":"Tislelizumab: A modified anti-tumor programmed death receptor 1 antibody","volume":"29","author":"Zhang","year":"2022","journal-title":"Cancer Control"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.4003","article-title":"Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: A phase 3 randomized clinical trial","volume":"9","author":"Qin","year":"2023","journal-title":"JAMA Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1075916","article-title":"Hepatitis B HBsAg clearance and immune response","volume":"13","author":"Zheng","year":"2022","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.10.010","article-title":"Patients with HCC as an ideal study population to assess immune checkpoint inhibitors in hepatitis B","volume":"82","author":"Xiao","year":"2025","journal-title":"J Hepatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00401","article-title":"Checkpoint inhibitors and therapeutic vaccines for the treatment of chronic HBV infection","volume":"73","author":"Hoogeveen","year":"2020","journal-title":"J Hepatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1159\/000534535","article-title":"Possibility of PD-1\/PD-L1 inhibitors for the treatment of patients with chronic hepatitis B infection","volume":"42","author":"Su","year":"2024","journal-title":"Dig Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01037","article-title":"Anti\u2013PD-1\/PD-L1 blockade immunotherapy employed in treating hepatitis B virus infection\u2013related advanced hepatocellular carcinoma: A literature review","volume":"11","author":"Li","year":"2020","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-02978-7","article-title":"Prompt initiation of durvalumab and tremelimumab for unresectable hepatocellular carcinoma in patients with chronic active hepatitis B: a phase 2 clinical trial","volume":"132","author":"Shao","year":"2025","journal-title":"Br J Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41389-023-00468-0","article-title":"Anti-PD-1 therapy achieves favorable outcomes in HBV-positive non-liver cancer","volume":"12","author":"Zhou","year":"2023","journal-title":"Oncogenesis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jhep.2024.07.018","article-title":"Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy","volume":"82","author":"Mon","year":"2025","journal-title":"J Hepatol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1007\/s00432-022-04133-8","article-title":"Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis","volume":"149","author":"Ding","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e091708","DOI":"10.1136\/bmjopen-2024-091708","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events: a retrospective study from VigiBase update in 2024 looking for emergent safety signals","volume":"14","author":"L\u2019Orphelin","year":"2024","journal-title":"BMJ Open"},{"key":"B36","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s11011-025-01645-3","article-title":"Blood-brain barrier dysfunction in hepatic encephalopathy: pathophysiology, diagnostic assessment and therapeutic perspectives","volume":"40","author":"Le Guennec","year":"2025","journal-title":"Metab Brain Dis"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1002\/agt2.552","article-title":"Rhein-based Pickering emulsion for hepatocellular carcinoma: Shaping the metabolic signaling and immunoactivation in transarterial chemoembolization","volume":"5","author":"Liang","year":"2024","journal-title":"Aggregate"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24087640","article-title":"Predictive biomarkers for immune-checkpoint inhibitor treatment response in patients with hepatocellular carcinoma","volume":"24","author":"Ji","year":"2023","journal-title":"Int J Mol Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1676514\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T06:15:32Z","timestamp":1763619332000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1676514\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2025.1676514"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1676514","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"article-number":"1676514"}}